Katy Beckermann: New CAIX-Targeting Tracer Outperforms FDG PET in Kidney Cancer Staging
Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared on X: “Staging kidney cancer with FDG PET has never really worked. A tracer aimed at CAIX, the […]
Read the full articleYou might also wanna read
Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC
Conditions : NSCLC; EGFR Activating Mutation; EGFR-TKI-resistant Non-Small Cell Lung Cancer; Trop2; PET/CT Imaging Interventions : Diagnosti
Two-isotope imaging could guide targeted alpha therapy for metastatic prostate cancer
Prostate cancer is one of the most common cancers affecting men worldwide. However, planning personalized radiotherapy in the advanced stage
GPC3-Targeted PET/CT in Hepatocellular Carcinoma
Conditions : Hepatocellular Carcinoma (HCC); Glypican-3; GPC3-targeted PET/CT Interventions : Diagnostic Test: 18F-FDG PET/CT and GPC3-targe
Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies
Abstract Purpose: For older patients with competing comorbidities, optimizing oncologic therapies is of paramount importance. Circulating tu
A Study of a New PET Scanner in People With Cancer
Conditions : Non Small Cell Lung Carcinoma NSCLC; Head and Neck Cancer; Prostate Cancer Interventions : Diagnostic Test: Biograph Vision Qua
FDA denies Lantheus’ application for new PET imaging agent
The Bedford, Massachusetts-based manufacturer has for months sought to roll out LNTH-2501—a radioactive diagnostic kit for localizing neuroe
Comments
Sign in to join the conversation.
No comments yet. Be the first.